Activated CD8+ T cells inhibit ferroptosis by binding to TYRO3 and promote the development of a pro-tumor microenvironment by decreasing the M1/M2 macrophage ratio, leading to resistance to anti-PD-1/PD-L1 therapy (255). Here, CD8A is linked to neoplasm.